Reports
Reports
Sale
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cancer Registry Software Market Overview
3.1 Global Cancer Registry Software Market Historical Value (2017-2023)
3.2 Global Cancer Registry Software Market Forecast Value (2024-2032)
4 Global Cancer Registry Software Market Landscape
4.1 Global Cancer Registry Software Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cancer Registry Software Product Landscape
4.2.1 Analysis by Software Type
4.2.2 Analysis by Database
4.2.3 Analysis by Deployment Type
4.2.4 Analysis by Functionality
5 Global Cancer Registry Software Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cancer Registry Software Market Segmentation
6.1 Global Cancer Registry Software Market by Software Type
6.1.1 Market Overview
6.1.2 Standalone
6.1.3 Integrated
6.2 Global Cancer Registry Software Market by Database
6.2.1 Market Overview
6.2.2 Public Data
6.2.3 Commercial Data
6.3 Global Cancer Registry Software Market by Deployment Type
6.3.1 Market Overview
6.3.2 Cloud-based
6.3.3 On-Premises
6.4 Global Cancer Registry Software Market by Functionality
6.4.1 Market Overview
6.4.2 Cancer Reporting
6.4.3 Patient Care
6.4.4 Medical Research
6.5 Global Cancer Registry Software Market by End User
6.5.1 Market Overview
6.5.2 Government Organization
6.5.3 Hospital and Medical Practices
6.5.4 Research Centres and Private Payers
6.5.5 Pharmaceutical, Biotechnology and Medical Device Companies
6.5.6 Others
6.6 Global Cancer Registry Software Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Cancer Registry Software Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cancer Registry Software Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cancer Registry Software Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cancer Registry Software Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cancer Registry Software Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding & Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Centers for Disease Control and Prevention
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisitions
16.1.5 Certifications
16.2 IBM Corporation
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Onco, Inc
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Elekta AB (pub)
16.4.1 Financial Analysis
16.4.2 Financial Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 C/NET Solution
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Ordinal Data, Inc
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Conduent, Inc
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 himagine solutions
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 McKesson Corporation
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 IACR Official Website
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 F. Hoffmann-La Roche Ltd
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
16.12 NeuralFrame, Inc
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisitions
16.12.5 Certifications
16.13 IARC
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisitions
16.13.5 Certifications
17 Global Cancer Registry Software Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 72.3 billion in 2023, driven by the prevalence of cancer cases across the globe.
The market is anticipated to grow at a CAGR of 10.4% during the forecast period of 2024-2032, likely to reach a market value of USD 175.8 billion by 2032.
Market demand has increased with the arrival of digital platforms and software to streamline patient data and develop customised treatment alternatives for them.
The current market trend involves the increasing prevalence of telemedicine, contributing to a significant surge in digital platforms and services. For example, in India, the National Cancer Grid has launched the Koita Centre for Digital Oncology (KCDO) to promote digital technologies and tools application for cancer treatment.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Software types include standalone and integrated.
Cancer reporting, patient care, and medical research are the major functionality areas.
It includes cloud-based and on-premises deployment types.
Database is divided into public and commercial data.
Major end users include government organizations, hospital and medical practices, research centres and private payers, pharmaceutical, biotechnology, and medical device companies, among others.
Key players involved in the market are Centers for Disease Control and Prevention, IBM Corporation, Onco, Inc., Elekta AB (pub), C/NET Solution, Ordinal Data, Inc., Conduent, Inc., himagine solutions, McKesson Corporation, IACR Official Website, F. Hoffmann-La Roche Ltd, NeuralFrame, Inc and IARC.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.